These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35769111)

  • 21. Clinical Significance of
    Uhercik M; Sanders AJ; Owen S; Davies EL; Sharma AK; Jiang WG; Mokbel K
    Anticancer Res; 2017 Aug; 37(8):4249-4254. PubMed ID: 28739716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors.
    Chen H; Liu H; Ai J; Du X; Sun Y; Xiao S
    Clin Transl Oncol; 2022 Mar; 24(3):586-596. PubMed ID: 34741725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Convolutional neural network scoring and minimization in the D3R 2017 community challenge.
    Sunseri J; King JE; Francoeur PG; Koes DR
    J Comput Aided Mol Des; 2019 Jan; 33(1):19-34. PubMed ID: 29992528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TB-IECS: an accurate machine learning-based scoring function for virtual screening.
    Zhang X; Shen C; Jiang D; Zhang J; Ye Q; Xu L; Hou T; Pan P; Kang Y
    J Cheminform; 2023 Jul; 15(1):63. PubMed ID: 37403155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant Therapy With PD1/PDL1 Inhibitors for Human Cancers: A Systematic Review and Meta-Analysis.
    Jin Y; Wei J; Weng Y; Feng J; Xu Z; Wang P; Cui X; Chen X; Wang J; Peng M
    Front Oncol; 2022; 12():732814. PubMed ID: 35280727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Scoring ligand similarity in structure-based virtual screening.
    Zavodszky MI; Rohatgi A; Van Voorst JR; Yan H; Kuhn LA
    J Mol Recognit; 2009; 22(4):280-92. PubMed ID: 19235177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Normalizing molecular docking rankings using virtually generated decoys.
    Wallach I; Jaitly N; Nguyen K; Schapira M; Lilien R
    J Chem Inf Model; 2011 Aug; 51(8):1817-30. PubMed ID: 21699246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Convolutional Neural Network-based Virtual Screening.
    Shan W; Li X; Yao H; Lin K
    Curr Med Chem; 2021; 28(10):2033-2047. PubMed ID: 32452320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy.
    Basher F; Dhar P; Wang X; Wainwright DA; Zhang B; Sosman J; Ji Z; Wu JD
    J Hematol Oncol; 2020 Jun; 13(1):74. PubMed ID: 32517713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.
    Four M; Cacheux V; Tempier A; Platero D; Fabbro M; Marin G; Leventoux N; Rigau V; Costes-Martineau V; Szablewski V
    Hematol Oncol; 2017 Dec; 35(4):487-496. PubMed ID: 27966264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1(+) cancer therapy.
    Tang X; Li Q; Zhu Y; Zheng D; Dai J; Ni W; Wei J; Xue Y; Chen K; Hou W; Zhang C; Feng X; Liang Y
    Am J Transl Res; 2015; 7(3):460-73. PubMed ID: 26045887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis.
    Jiang Q; Huang J; Zhang B; Li X; Chen X; Cui B; Li S; Guo G
    Front Immunol; 2022; 13():801909. PubMed ID: 35309350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy.
    Liu J; Chen Z; Li Y; Zhao W; Wu J; Zhang Z
    Front Pharmacol; 2021; 12():731798. PubMed ID: 34539412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.
    Tzeng A; Diaz-Montero CM; Rayman PA; Kim JS; Pavicic PG; Finke JH; Barata PC; Lamenza M; Devonshire S; Schach K; Emamekhoo H; Ernstoff MS; Hoimes CJ; Rini BI; Garcia JA; Gilligan TD; Ornstein MC; Grivas P
    Target Oncol; 2018 Oct; 13(5):599-609. PubMed ID: 30267200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression.
    Haile ST; Dalal SP; Clements V; Tamada K; Ostrand-Rosenberg S
    J Immunol; 2013 Sep; 191(5):2829-36. PubMed ID: 23918985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recurrent PDL1 expression and PDL1 (CD274) copy number alterations in breast implant-associated anaplastic large cell lymphomas.
    Tabanelli V; Corsini C; Fiori S; Agostinelli C; Calleri A; Orecchioni S; Melle F; Motta G; Rotili A; Di Napoli A; Pileri SA
    Hum Pathol; 2019 Aug; 90():60-69. PubMed ID: 31125630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blocking PD1/PDL1 Interactions Together with MLN4924 Therapy is a Potential Strategy for Glioma Treatment.
    Filippova N; Yang X; An Z; Nabors LB; Pereboeva L
    J Cancer Sci Ther; 2018; 10(8):190-197. PubMed ID: 30393513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beware of Simple Methods for Structure-Based Virtual Screening: The Critical Importance of Broader Comparisons.
    Tran-Nguyen VK; Ballester PJ
    J Chem Inf Model; 2023 Mar; 63(5):1401-1405. PubMed ID: 36848585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer.
    Ren X; Wu H; Lu J; Zhang Y; Luo Y; Xu Q; Shen S; Liang Z
    Cancer Biol Ther; 2018 May; 19(5):373-380. PubMed ID: 29336717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients.
    Xing X; Guo J; Ding G; Li B; Dong B; Feng Q; Li S; Zhang J; Ying X; Cheng X; Guo T; Du H; Hu Y; Zhou T; Wang X; Li L; Li Q; Xie M; Li L; Gao X; Shan F; Li Z; Jia S; Wen X; Wang J; Ji J
    Oncoimmunology; 2018; 7(3):e1356144. PubMed ID: 29399387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.